Omaha、NEにおける多発性骨髄腫の臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
被験者募集中第1/2相
- Nebraska Cancer Institute, Omaha
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
被験者募集中
- University of Nebraska Medical Center, Omaha
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
被験者募集中第1相
- University of Nebraska, Omaha
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
被験者募集中
- Unversity of Nebraska Medical Center, Omaha
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- University Of Nebraska Medical Center, Omaha
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Halt Aging in Survivors of Blood Cancers
被験者募集中
- University of Nebraska Medical Center, Omaha
Integrated Cancer Repository for Cancer Research
被験者募集中観察研究健康なボランティア歓迎
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- 他1件
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
被験者募集中第3相
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
- 他1件
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- Nebraska Cancer Specialists, Omaha
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Omahaにおける他の研究
- 前立腺がん27件の研究
- 非小細胞肺癌24件の研究
- 乳がん22件の研究
- 大腸癌18件の研究
- がん（全種類）18件の研究
- 非ホジキンリンパ腫14件の研究
- 卵巣がん14件の研究
- 膵臓がん14件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 転移性癌13件の研究
- 腎臓がん（腎細胞がん）12件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。